Viewing Study NCT01198301



Ignite Creation Date: 2024-05-05 @ 10:50 PM
Last Modification Date: 2024-10-26 @ 10:24 AM
Study NCT ID: NCT01198301
Status: COMPLETED
Last Update Posted: 2015-07-23
First Post: 2010-09-09

Brief Title: Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy
Sponsor: Peking University Cancer Hospital Institute
Organization: Peking University Cancer Hospital Institute

Study Overview

Official Title: Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy
Status: COMPLETED
Status Verified Date: 2015-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The investigators want to develop a gene expression profile the for prediction the chemotherapeutic response of patients with metastatic breast cancer
Detailed Description: 1 Metastatic breast cancer tissue is obtained from core needle biopsies pretreatment and is flash frozen and stored at -70 until processing
2 After patients received docetaxel combination thiotepa for two cycles response is assessed using Response Evaluation Criteria in Solid Tumor Group RECIST guidelines Degree of response is used to divide the cancers into two groups-sensitive and resistant tumours
3 The gene expression in metastatic breast cancer tissue sample is detected by microarray to screen gene markers that are differently expressed between groups
4 Statistical analysis is performed using unsupervised hierarchical cluster

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None